Literature DB >> 7881194

Drug kinetics and drug resistance in optimal chemotherapy.

M I Costa1, J L Boldrini, R C Bassanezi.   

Abstract

A system of differential equations for the control of tumor cells growth in a cycle nonspecific chemotherapy is presented. First-order drug kinetics and drug resistance are taken into account in a class of optimal control problems. The results show that the strategy corresponding to the maximum rate of drug injection is optimal for the Malthusian model of cell growth (which is a relatively good model for the initial phase of tumor growth). For more general models of cell growth, this strategy proved to be suboptimal under certain conditions.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7881194     DOI: 10.1016/0025-5564(94)00027-w

Source DB:  PubMed          Journal:  Math Biosci        ISSN: 0025-5564            Impact factor:   2.144


  7 in total

Review 1.  Evolution of acquired resistance to anti-cancer therapy.

Authors:  Jasmine Foo; Franziska Michor
Journal:  J Theor Biol       Date:  2014-03-25       Impact factor: 2.691

2.  Tackling the problems of tumour chemotherapy by optimal drug scheduling.

Authors:  Ambili Remesh
Journal:  J Clin Diagn Res       Date:  2013-05-31

Review 3.  Improving Cancer Treatment via Mathematical Modeling: Surmounting the Challenges Is Worth the Effort.

Authors:  Franziska Michor; Kathryn Beal
Journal:  Cell       Date:  2015-11-19       Impact factor: 41.582

4.  How to Use a Chemotherapeutic Agent When Resistance to It Threatens the Patient.

Authors:  Elsa Hansen; Robert J Woods; Andrew F Read
Journal:  PLoS Biol       Date:  2017-02-09       Impact factor: 8.029

5.  Optimal dynamic control approach in a multi-objective therapeutic scenario: Application to drug delivery in the treatment of prostate cancer.

Authors:  Itziar Irurzun-Arana; Alvaro Janda; Sergio Ardanza-Trevijano; Iñaki F Trocóniz
Journal:  PLoS Comput Biol       Date:  2018-04-19       Impact factor: 4.475

6.  Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies.

Authors:  Jasmine Foo; Franziska Michor
Journal:  PLoS Comput Biol       Date:  2009-11-06       Impact factor: 4.475

7.  Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients.

Authors:  Lin L Liu; Fei Li; William Pao; Franziska Michor
Journal:  PLoS One       Date:  2015-11-04       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.